

Outlook Therapeutics, Inc. Logo

## Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

September 21, 2021

**Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET**

ISELIN, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that [C. Russell Trenary, President and Chief Executive Officer](#) of Outlook Therapeutics, will participate in a fireside chat hosted by Kristen Kluska, Director, Equity Research at the [Cantor Fitzgerald Virtual Global Healthcare Conference](#) on Tuesday, September 28, 2021 at 2:00 PM ET.

In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the [conference website](#).

A [live webcast](#) of the fireside chat will be accessible on the [Events](#) page in the [Investors](#) section of the Outlook Therapeutics website ([outlooktherapeutics.com](#)) and accessible for 90 days following the event.

### About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit [www.outlooktherapeutics.com](#).

### CONTACTS:

#### Media Inquiries:

Harriet Ullman  
Vice President  
LaVoie Health Science  
T: 617-669-3082  
[hullman@lavoiehealthscience.com](mailto:hullman@lavoiehealthscience.com)

#### Investor Inquiries:

Jenene Thomas  
Chief Executive Officer  
JTC Team, LLC  
T: 833.475.8247  
[OTLK@jtcir.com](mailto:OTLK@jtcir.com)



Source: Outlook Therapeutics, Inc.